Men and women may be affected differently by retinitis pigmentosa, a disease that causes blindness over time. That's ...

Presentation title : Subretinal gene therapy laru-zova for X-linked retinitis pigmentosa (XLRP): Phase 2 DAWN trial, preliminary month 9+ results Date : Thursday, September 4, 2025 Presenter : Rajiv ...

Aldeyra Therapeutics received FDA fast track designation for ADX-2191 for the treatment of retinitis pigmentosa, according to ...

ADX-2191 is a preservative-free intravitreal formulation of methotrexate designed to treat various rare retinal diseases such as retinitis pigmentosa.

Retinitis pigmentosa (RP) is a term for a group of eye diseases that can lead to loss of sight. What they have in common are specific changes your doctor sees when they look at your retina – a ...

NEWPORT BEACH, Calif., August 18, 2025--jCyte, Inc. is pleased to announce the first patients have been enrolled and treated ...

Aldeyra (ALDX) announced that the FDA has granted fast track designation for ADX-2191 for the treatment of retinitis pigmentosa. There is ...

This work can be read in the journal PLOS Biology. Retinitis pigmentosa is the most common hereditary retinal disease in humans, with a prevalence of one in every 4,000 people worldwide.

Retinitis Pigmentosa Market Dublin, June 26, 2025 (GLOBE NEWSWIRE) -- The "Retinitis Pigmentosa Market Opportunities and Strategies to 2034" report has been added to ResearchAndMarkets.com's offering.

Documentary focusing on Dave Steele, aka the Blind Poet, as he faces final sight loss due to the condition retinitis ...